FEATURE
B:15.5”
T:15.25”
and grow as palliative-care consults
become more common, Dr. El-Jawahri
said. During the HCT study, she and
her colleagues noticed that transplant
clinicians began paying closer attention
to the recommendations offered during
the palliative-care consults and symptom
management. For instance, transplant
physicians were more likely to use antipsychotics for the management of nausea
in patients assigned to the intervention
arm and, after the study, the researchers
also noted a higher use of these drugs in
patients getting standard care.
“The transplant clinicians involved
in the study saw that this treatment
was beneficial and started to apply it to
patients who were receiving standard care
– and to patients outside of the study,” she
explained.
G:.5”
Primary palliative care is not a onesize-fits-all approach, so education will
need to be tailored to the needs of hematologists, nurse practitioners, transplant
physicians, and other members of the
care team – as well as to the needs of the
patients they treat.
“A huge part of that is going to be taking successful interventions examined in
studies like ours, distilling them to their
essential components, and conducting
studies that integrate those components
into clinical practice,” she added.
Patients also will need education
about palliative care and, according to
Dr. LeBlanc, that will need to come from
their physicians. “When a referral to
a palliative-care clinician is needed, it
will be important for hematologists to
understand the benefits and the reasons
S:6.75”
BOSULIF offers proven efficacy for patients with resistance or intolerance to prior therapy2
In 2nd-line treatment, after imatinib (n=266 evaluable)a
34
%
of patients
53
%
of patients
achieved MCyR at 6 months achieved MCyR with a minimum
follow-up of 23 months
(95% CI: 28.2, 39.9)
Median duration of MCyR was not
reached at the time of analysis
53% of patients with MCyR maintained
MCyR for at least 18 months (with a
minimum follow-up of 23 mon